Celldex Therapeutics Inc has hit a technical signal on 3 different technical indicators. CLDX is in the Health Care sector. The technical signals indicate that the stock is Overbought right now. The 3 indicators: Commodity Channel Index, Relative Strength Index and the Fast Stochastics were all triggered based on the last closing price of $4.97 on Feb. 1.
There are currently 5 analysts covering the company. Of these analysts, 4 have a buy recommendation.
Over the last 52 weeks, the stock has been trading between $2.05 and $5.00. More recently in the last 4 weeks, the stock has been trading between $2.73 and $5.00. Yesterday the stock traded between $4.75 and $5.00. The stock currently has a PE ratio of 0.0.
Celldex Therapeutics Inc is trading 32.2% from its 20-day simple moving average (SMA) of $3.76 and 58.7% from its 50-day SMA and 57.52% from its 200-day SMA. Average daily volume over the last 30 days has been 592,543 shares.
At yesterdays close: the RSI was at 88.7, the CCI was at 139.7 and the Fast Stochastic was at 98.4. CLDX closed yesterday at $4.97, on volume of 1,064,661 shares as compared to an average volume of 592,543 over the last 4 weeks.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of novel therapeutics for human health care. The company offers Rotarix for the treatment of rotavirus infection. Its clinical development programs include CDX-110 (rindopepimut), which is in Phase IIb clinical trial for the treatment of glioblastoma multiforme; CDX-011 (glembatumumab vedotin) that is in Phase IIb clinical trial to treat metastatic breast cancer and melanoma; CDX-1307, a Phase II clinical trial product for treating muscle-invasive bladder cancer; and CDX-1401, which is in Phase I/II clinical trials for the treatment of multiple solid tumors. The company's preclinical product candidates comprise CDX-301 for treating cancer, and autoimmune diseases and transplants; CDX-1127 for immuno-modulation and multiple tumors; CDX-014 to treat renal and ovarian cancer; and CDX-1135, a complement inhibitor that suppresses inflammatory reactions. It has research collaboration and licensing agreements with Medarex, Inc.; Alteris Therapeutics, Inc.; 3M Company; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc., as well as partnership agreements with GlaxoSmithKline plc; Pfizer Inc.; Vaccine Technologies, Inc.; and TopoTarget A/S. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
Technical Indicators should be used as the starting point for further analysis. These indicators are provided as a guide to help you determine what assets to analyze. The technical indicators used in this article can indicate that an asset is either overbought or oversold, but that indication could be the result of a fundamental or other type of event like an earnings announcement.
To learn more about technical analysis, please refer to our technical analysis primer.
| Porfolios Holding CLDX | Technical Analysis on TheStreet by Fred Meissner |
| TheStreet Ratings Report for CLDX | Read more on Technical Analysis from Tim Collins on RealMoney.com |
| ETFs Holding CLDX |
